Key Segments:
By Product & Services
-
Products
-
Services
By Type
-
CRISPR Knockout
-
CRISPR Interference
-
CRISPR Activation
-
Others
By Application
-
Functional Genomics
-
Drug Discovery and Development
-
Target Identification and Validation
-
Cancer Research
-
Genetic Disease Research
By End Use
-
Pharmaceutical and Biotechnology Companies
-
Academic and Research Institutes
-
Contract Research Organizations
-
Other End Users
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Revvity, Thermo Fisher Scientific, Merck KGaA, Cellecta, GeneCopoeia, Integrated DNA Technologies, bit.bio, Horizon Discovery and Applied Biological Materials, among others. These companies compete on library breadth, reagent quality and screening service capability.
The main opportunities lie in pairing AI-enabled guide RNA design and data analysis tools with existing reagent and library catalogs, and extending accessible screening capability to contract research organizations and smaller biotechnology companies in emerging markets.
The key growth factor is rising demand for the reagents and instruments underpinning genome-scale screening, reinforced by growing commercial validation from approved CRISPR-based therapies that encourages earlier-stage investment in target discovery screening.
By application, the Functional Genomics segment dominated the market with approximately 31.20% share in 2025, supported by its broad, hypothesis-generating use across academic and industry research.
North America dominated the market with approximately 41.80% share in 2025, supported by its dense concentration of pharmaceutical discovery units and academic genome centers. Asia Pacific is the fastest-growing region with a projected CAGR of 18.50% from 2026 to 2035.
